Yahoo Malaysia Web Search

Search results

  1. Jun 30, 2022 · Alexandra Eitel, MBA ’22, sits down with Anne Wojcicki, co-founder and CEO of 23andMe to discuss breaking down inequality through genetics and how leaders should build trust by being unabashedly honest. “The guiding principle for 23andMe is transparency and choice. It’s the choice whether you want to get your genetic information, the ...

  2. Apr 29, 2022 · Anne Wojcicki, Co-Founder of 23andMe: Making Her Own Way. Post grad, Wojcicki began working as a healthcare consultant at Passport Capital and at Investor AB. Passport Capital is an investment fund based in San Francisco. For four years, she worked as a healthcare investment analyst.

  3. Feb 2, 2024 · Anne Wojcicki, chief executive officer and co-founder of 23andMe Inc., speaks during the 2020 Makers Conference in Los Angeles, California, U.S., on Tuesday, Feb. 11, 2020. Kyle Grillot/Bloomberg ...

  4. Join our diverse team of ever-curious scientists, engineers, researchers, marketers and many more who share one common goal–to make a difference in people’s lives. Check out our job openings here. 23andMe is a genetics and health company that believes you should be able to access, understand and benefit from all the endlessly interesting ...

  5. Liked by Anne Wojcicki. Experience: 23andMe · Location: Mountain View · 500+ connections on LinkedIn. View Anne Wojcicki’s profile on LinkedIn, a professional community of 1 billion members.

  6. Apr 6, 2023 · Wojcicki, founder of pioneering DNA testing company 23andMe, sees much of the world—stubbornness included—through the lens of genetics. “You have genes and you have environment,” Wojcicki says, reclining on her balcony in the casual garb that has long defined her personal style—puffy jacket, workout shorts and Crocs.

  7. Nov 7, 2023 · 23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’. 23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more. Published Nov. 7, 2023. By Alexandra Pecci.